The American Society for Radiation Oncology (ASTRO)
Since the first independent scientific meeting held in 1970 by the Society, back when it was known simply as ASTR, or, American Society of Therapeutic Radiologists, their annual meetings held all over the United States have continued to grow and thrive. Now, 55 years later, ASTRO meetings are an unmissable event in the calendars of all radiotherapy professionals. Each year, the increasing number of actors that have taken radiation oncology as a discipline to its current heights are provided with a common platform to present and discuss the latest advances in cancer care. This year’s event at the Moscone Center in San Francisco, from September 27 to October 1 will be no exception, and THERYQ’s team will be there to discuss all things FLASH radiotherapy.
FLASH Radiotherapy, a Groundbreaking Innovation in Radiotherapy Research
This year’s theme is Rediscovering Radiation Medicine and Exploring New Indications, a message that draws a quintessential parallel with the story of FLASH radiotherapy.
FLASH Radiotherapy is an innovative radiation technique in which treatment is delivered in a fraction of a second, at an ultra-high dose rate (commonly referred to using the acronym “UHDR”). Using this method, a remarkable biological effect can be observed, with pre-clinical research showing an enhanced differential response. Damage to surrounding healthy tissue is reduced with a maintained level of tumor control compared to conventional treatments.
The study of the FLASH effect challenges our assumptions about the effects of radiation and offers a glimpse into how exploring the current tools of radiotherapy can lead to new hopes for patients. By paving the way towards faster, better tolerated treatments, FLASH radiotherapy could bring about a new chapter for radiation oncology, with the potential to redefine its current limitations.
FLASH radiotherapy is a novel technique, delivering radiation at ultra-high dose rates in a fraction of a second. This modality is currently being studied and is not clinically available.
THERYQ, Pioneers in FLASH Radiotherapy
THERYQ specializes in the development of FLASH Radiotherapy devices, with a view to pioneering the clinical application of the innovation. For over a decade, THERYQ’s teams have partnered with various leading cancer research centers in collaborative FLASH research projects. As our portfolio of UHDR electron beam linacs continues to grow, we are proud to be an industrial partner with solutions for every step of the journey from pre-clinical research to clinical translation.
Want to meet with our team in San Francisco? Contact THERYQ or book a timeslot using the button below.